Hengrui's new drug R&D pipeline revealed!

TextGood Lentils

In the early 1970s, the successful launch of Dongfanghong-1 opened a new era in China's aerospace history

At the same time, a pharmaceutical company making red syrup was born in Lianyungang, Jiangsu

More than 50 years later, this red medicine company has become a "bright red" in China's pharmaceutical industry

A research and development team of more than 4,700 people, more than 400 clinical trial institutions across the country, an average of nearly 200 research centers are launched every month, and an average of more than 700 subjects are enrolled every month.

What medicines are sold in Hengrui's gourd?

50+ innovative drug clinical development

As a pioneer and leader of innovative drug research and development in China, Hengrui Medicine has currently approved 10 innovative drugs for marketing, and more than 50 innovative drugs are in clinical development, of which 15 are in phase III clinical research and have submitted marketing applications, and 40 The rest are in Phase I-II clinical research stage

More than 240 clinical trials have been carried out at home and abroad, and 24 innovative drug projects have been approved to conduct global multi-center or regional clinical research

Since Hengrui Medicine's first innovative drug erecoxib was approved for marketing in 2011, Hengrui Medicine's innovative achievements have been gradually iterated and the results have continued to emerge

In 2018, the results began to explode, and 3 innovative drugs were approved for marketing in 2021 (Heptopa ethanolamine tablets, Dalcilis isethionate tablets and Proline Henggliflozin tablets)

Table 1 Hengrui Medicine's approved innovative drugs

Flexible grid layout

Under the pressure of centralized procurement, Hengrui Medicine accelerated the adjustment of its development strategy and redefines innovation

From the fast-follow in the early 21st century, it has gradually begun to explore new targets in recent years, and fully explore the potential of the targets under study in various indications, and explore new indications

The innovation network of Hengrui Medicine is becoming more and more flexible and attractive

From the perspective of the layout of innovative R&D pipelines, Hengrui Medicine has a strong focus on tumors, and the sub-fields involved include traditional kinase inhibitors, emerging antibody-drug conjugates (ADCs), tumor immunology, hormone receptor regulation, DNA repair and epigenetics Genetics and supportive care in oncology

In addition, multiple therapeutic areas such as autoimmune diseases, pain, cardiovascular, metabolic diseases, infectious diseases, respiratory diseases and neurological diseases have also achieved forward-looking layout, and the R&D pipeline has become increasingly diversified

The distribution of therapeutic areas of research projects in 2021:

The proportions of tumors, autoimmunity, metabolic diseases, cardiovascular diseases and others in small molecules are 55%, 18%, 8%, 4% and 15% in sequence; in macromolecules, the proportions of tumors, nervous system, autoimmunity and cardiovascular disease in sequence were 72%, 16%, 8% and 4%

Figure 1 Hengrui Medicine's domestic innovative drug clinical R&D pipeline

Source: Public information of Hengrui R&D day

Figure 2 Hengrui Medicine's overseas innovative drug clinical R&D pipeline

Source: Public information of Hengrui R&D day

Shigekura tumor

Epidemiological changes have gradually evolved from "talking about tumor discoloration" to "talking about chronic disease discoloration"

Hengrui Medicine has always been aware of the risk of "walking with multiple legs":

In the stage of combination of imitation and innovation, Hengrui Medicine has basically achieved the three pillars of anti-tumor drugs, surgical drugs and imaging intervention products; in the innovation-driven stage, Hengrui is close to being divided into two parts of tumor and chronic disease treatment from a larger category

In the field of tumor treatment, Hengrui Medicine firmly believes that more and more patients will benefit from innovative treatment methods, and malignant diseases will eventually be transformed into chronic diseases or even cured
.

In the tumor layout, Hengrui's research and development varieties basically cover the high-incidence tumor types in China, especially lung cancer and breast cancer
.

Lung Cancer Treatment

Full coverage for non-squamous NSCLC, squamous NSCLC, driver gene-positive NSCLC, SCLC subtypes, carelizumab, carelizumab + famitinib, PD-L1 mAb, PD-L1/TGF- β double antibody, PD-L1/TGF-β + famitinib, PD-L1/TGF-β + bevacizumab, pyrotinib, HER2 ADC and other single drugs and combination matrices are solid and powerful
.

Table 2 Hengrui Medicine is in clinical practice in the field of lung cancer

and the main product layout at the launch stage

Breast Cancer Layout

HER2-positive breast cancer, HR+, HER- breast cancer, BRAC mutation, TNBC and other common and rare subtypes have also achieved extensive coverage.
Adjuvant therapy is achieved in echelon standing
.

In addition, tumor types with high incidence in China such as liver cancer, gastric cancer, prostate cancer, ovarian cancer, and cervical cancer are also poised to develop, and multiple products go hand in hand, which is expected to further complement Hengrui Medicine's dominant position in the field of oncology
.

A forward-looking layout has been achieved in great strides on new targets and new mechanisms:

PEG-IL-2, ERKi, SERCA, TIM-3, LAG-3, Claudin 18.
2ADC; subcutaneous PD-1, EZH2i, ATRi, MCL-1i, AKTi and other new targets became the first batch of "crab-eating" in China innovative enterprise
.

Table 3 Hengrui Medicine is in clinical practice in the field of breast cancer

and the main product layout at the launch stage

Source: Hengrui official website

Long and short-acting multiple coverage

Hengrui's chronic disease treatment covers metabolic diseases, cardiovascular diseases, respiratory diseases, autoimmune diseases, pain management, bone metabolism,
etc.

Table 4 Representative pipeline layout of Hengrui Medicine in the field of chronic disease treatment

In particular, metabolic diseases represented by diabetes and autoimmune diseases represented by rheumatoid arthritis have formed a combination covering mature targets, popular products, and new indications for targets, laying a solid foundation for the development of chronic disease products
.

Extensive combination of macromolecules and small molecules, short-acting and long-acting multi-innovation, to achieve all-round and multi-organ coverage according to the disease process
.
In the current pipeline of chronic diseases, there are basically valuable differentiated innovations that can meet clinical needs
.

Figure 3 The key pipeline layout of Hengrui Medicine in the field of diabetes

Source: Public information of Hengrui R&D day

In addition, Hengrui Medicine also has some layouts in emerging fields, such as ophthalmology and radionuclides, and the iterative, complementary and gain effects of pipelines are gradually emerging
.